Patrick Nasarre

Title
InstitutionMedical University of South Carolina
DepartmentOncologic and Endocrine Surgery
AddressP.O. Box MSC 613
710
86 Jonathan Lucas St.
Phone843-792-5722
Fax843-792-3315
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Nasarre P, Garcia DI, Siegel JB, Bonilla IV, Mukherjee R, Hilliard E, Chakraborty P, Nasarre C, Yustein JT, Lang M, Jaffa AA, Mehrotra S, Klauber-DeMore N. Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma. Cancers (Basel). 2021 May 30; 13(11). PMID: 34070758.
      Citations:    
    2. Dimou A, Nasarre C, Peterson YK, Pagano R, Gooz M, Nasarre P, Drabkin HA, Armeson KE, Gibney BC, Gemmill RM, Denlinger CE. Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021 08; 162(2):463-473. PMID: 32653291.
      Citations:    
    3. Garcia D, Nasarre P, Bonilla IV, Hilliard E, Peterson YK, Spruill L, Broome AM, Hill EG, Yustein JT, Mehrotra S, Klauber-DeMore N. Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo. Ann Surg Oncol. 2019 Dec; 26(13):4782-4790. PMID: 31515721.
      Citations:    
    4. Chakraborty P, Chatterjee S, Kesarwani P, Thyagarajan K, Iamsawat S, Dalheim A, Nguyen H, Selvam SP, Nasarre P, Scurti G, Hardiman G, Maulik N, Ball L, Gangaraju V, Rubinstein MP, Klauber-DeMore N, Hill EG, Ogretmen B, Yu XZ, Nishimura MI, Mehrotra S. Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells. J Biol Chem. 2019 06 07; 294(23):9198-9212. PMID: 30971427.
      Citations:    
    5. Nasarre P, Bonilla IV, Metcalf JS, Hilliard EG, Klauber-DeMore N. TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res. 2018 06; 28(3):185-194. PMID: 29553967.
      Citations:    
    6. Peterson YK, Nasarre P, Bonilla IV, Hilliard E, Samples J, Morinelli TA, Hill EG, Klauber-DeMore N. Frizzled-5: a high affinity receptor for secreted frizzled-related protein-2 activation of nuclear factor of activated T-cells c3 signaling to promote angiogenesis. Angiogenesis. 2017 Nov; 20(4):615-628. PMID: 28840375.
      Citations:    
    7. Gemmill RM, Nasarre P, Nair-Menon J, Cappuzzo F, Landi L, D'Incecco A, Uramoto H, Yoshida T, Haura EB, Armeson K, Drabkin HA. The neuropilin 2 isoform NRP2b uniquely supports TGFß-mediated progression in lung cancer. Sci Signal. 2017 01 17; 10(462). PMID: 28096505.
      Citations:    
    8. Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H. Erratum: Roche, J. et al. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers, 2013, 5, 334-356. Cancers (Basel). 2016 12 15; 8(12). PMID: 27983677.
      Citations:    
    9. Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One. 2016; 11(1):e0147344. PMID: 26789630.
      Citations:    
    10. Nasarre P, Gemmill RM, Drabkin HA. The emerging role of class-3 semaphorins and their neuropilin receptors in oncology. Onco Targets Ther. 2014; 7:1663-87. PMID: 25285016.
      Citations:    
    11. Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA. Neuropilin-2 Is upregulated in lung cancer cells during TGF-ß1-induced epithelial-mesenchymal transition. Cancer Res. 2013 Dec 01; 73(23):7111-21. PMID: 24121493.
      Citations:    
    12. Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers (Basel). 2013 Apr 03; 5(2):334-56. PMID: 24216980.
      Citations:    
    13. Testori J, Schweighofer B, Helfrich I, Sturtzel C, Lipnik K, Gesierich S, Nasarre P, Hofer-Warbinek R, Bilban M, Augustin HG, Hofer E. The VEGF-regulated transcription factor HLX controls the expression of guidance cues and negatively regulates sprouting of endothelial cells. Blood. 2011 Mar 03; 117(9):2735-44. PMID: 21224470.
      Citations:    
    14. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 2011 Jan 01; 300(1):66-78. PMID: 20980099.
      Citations:    
    15. Nasarre P, Potiron V, Drabkin H, Roche J. Guidance molecules in lung cancer. Cell Adh Migr. 2010 Jan-Mar; 4(1):130-45. PMID: 20139699.
      Citations:    
    16. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, Schadendorf D, Thurston G, Fiedler U, Augustin HG. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 2009 Feb 15; 69(4):1324-33. PMID: 19208839.
      Citations:    
    17. Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, Drabkin HA. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res. 2007 Sep 15; 67(18):8708-15. PMID: 17875711.
      Citations:    
    18. Potiron V, Nasarre P, Roche J, Healy C, Boumsell L. Semaphorin signaling in the immune system. Adv Exp Med Biol. 2007; 600:132-44. PMID: 17607952.
      Citations:    
    19. Nasarre P, Constantin B, Drabkin HA, Roche J. [Semaphorins and cancers : an up 'dating']. Med Sci (Paris). 2005 Jun-Jul; 21(6-7):641-7. PMID: 15985208.
      Citations:    
    20. Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia. 2005 May; 7(5):457-65. PMID: 15967098.
      Citations:    
    21. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, Roche J. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia. 2005 Feb; 7(2):180-9. PMID: 15802023.
      Citations:    
    22. Nasarre P, Constantin B, Rouhaud L, Harnois T, Raymond G, Drabkin HA, Bourmeyster N, Roche J. Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia. 2003 Jan-Feb; 5(1):83-92. PMID: 12659673.
      Citations:    
    Nasarre's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (166)
    Explore
    _
    Co-Authors (20)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _